Showing 201 results

Filters Content type: News, Editors' picks Topic: Treatment-experienced people

HIV treatment options for people who have a strain of HIV that is resistant to multiple drug classes.

Treatment-experienced people

Study Bite: Switching to B/F/TAF Plus Doravirine in Multidrug-Resistant PLWH

Editor's pick
TheBodyPro
5 May 2023
Treatment-experienced people

WEP Clinical has partnered with TaiMed Biologics to launch a Trogarzo named patient program

Editor's pick
WEP Clinical press release
24 March 2023
Injectable & long-acting HIV treatment

Lenacapavir Shows Continued Promise for People With Drug-Resistant HIV

Editor's pick
POZ
10 November 2022
HIV treatment

IDWeek 2022 Study Bites: What’s New in HIV Antiretroviral Therapy

Editor's pick
TheBodyPro
10 November 2022
Pharmaceutical industry

Long-suffering CytoDyn withdraws HIV approval application for leronlimab, blaming clinical research organization

Editor's pick
FierceBiotech
1 November 2022
Treatment-experienced people

Lenacapavir: 75% Sub-50 Response at 52 Weeks Despite Heavy ART Experience

Editor's pick
NATAP
26 October 2022
Treatment-experienced people

FDA Approves Trogarzo for 30-Second IV Push, Simplifying HIV Treatment for Heavily Treatment-Experienced People

Editor's pick
Infectious Disease Special Edition
5 October 2022
New & experimental HIV treatments

5 FDA decisions to watch in the fourth quarter

Editor's pick
BioPharma Dive
3 October 2022
New & experimental HIV treatments

Fostemsavir Plus Optimized Background Therapy May Be Viable for Multidrug-Resistant HIV

Editor's pick
Infectious Disease Advisor
30 June 2022
Injectable & long-acting HIV treatment

Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV

Editor's pick
Gilead Sciences press release
25 June 2022
Treatment-experienced people

Theratechnologies to Focus Its Commercialization Activities on the North American Territory

Editor's pick
Theratechnologies press release
28 April 2022
New & experimental HIV treatments

Top 5 HIV treatment stories from CROI 2022

News
2 March 2022
New & experimental HIV treatments

Lenacapavir shows continued promise for first-line treatment and highly resistant HIV

News
23 February 2022
Resistance

New cases of multi-drug resistant HIV becoming rarer in Europe

News
28 October 2021
Injectable & long-acting HIV treatment

Theratechnologies Announces Positive Results for Trogarzo® IV Push Administration Study

Editor's pick
GlobeNewswire
22 September 2021
New & experimental HIV treatments

Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing therapy

News
17 July 2021
Pharmaceutical industry

Gilead files long-acting HIV med for patients running out of options

Editor's pick
FierceBiotech
1 July 2021
New & experimental HIV treatments

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options

Editor's pick
Gilead press release
29 June 2021
Treatment-experienced people

Heavily treatment-experienced people in Europe do not have a higher risk of clinical events

News
1 April 2021
New & experimental HIV treatments

HIV capsid inhibitor offers new option for people with highly resistant HIV

News
10 March 2021
New & experimental HIV treatments

ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIV

Editor's pick
ViiV Healthcare press release
8 February 2021
New & experimental HIV treatments

ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available

Editor's pick
ViiV Healthcare press release
11 December 2020
HIV treatment

Top 10 HIV Clinical Developments of 2020

Editor's pick
TheBodyPro
1 December 2020
New & experimental HIV treatments

Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV

Editor's pick
Gilead press release
20 November 2020